Innovation Pharmaceuticals Inc (IPIX)

[slcimmuno]

SOM Incidence —
Active Relative to Placebo

This is the key measure – 28.5% in mITT and 38.7% PP

([incidence control - incidence active]/incidence control)

Good spread (prevention) and may improve further in a Ph3 if placebo rate falls more in line w historical norms of 70-75% (can even be higher in HNC) – this assumes B-OM active arm stays constant -- though active arm may perform better too

So ideal would be placebo does worse and active does better = greater spread as Prevention efficacy

“Overall reduction in observed severe Oral Mucositis (WHO Grade ≥ 3) in the Brilacidin-OM treatment group from that seen in the control group ([incidence control - incidence active]/incidence control) was: 28.5% (mITT population) and 38.7% (PP population).”